Health : Medical Research (Grantmaking)
Foundation for Angelman Syndrome Therapeutics
Cure Angelman Now.
Board Leadership
Paula M. Evans
Chairperson
CEO
Paula M. Evans
Chairperson
|
The Foundation for Angelman Syndrome Therapeutics (FAST) is committed to accelerating treatments and a cure for Angelman syndrome (AS). The symptoms of AS have been under-addressed in the research community for far too long. Research aimed at identifying treatments for the motor dysfunction, seizures and behavioral characteristics of Angelman syndrome is one of FAST's top priorities. Our goal is to bring practical treatment into current medical practice as quickly as possible. It is our hope that grants we fund will lead to additional research support from government agencies, other funding sources and organizations around the globe.
The Foundation for Angelman Syndrome Therapeutics (FAST) is committed to accelerating treatments and a cure for Angelman syndrome (AS). The symptoms of AS have been under-addressed in the research community for far too long. Research aimed at identifying treatments for the motor dysfunction, seizures and behavioral characteristics of Angelman syndrome is one of FAST's top priorities. Our goal is to bring practical treatment into current medical practice as quickly as possible. It is our hope that grants we fund will lead to additional research support from government agencies, other funding sources and organizations around the globe.
Impact Information
Financial
100.00
Accountability & Transparency
89.00

Program Expenses (Percent of the charity's total expenses spent on the programs and services it delivers) |
93.1% | |
Administrative Expenses | 3.3% | |
Fundraising Expenses | 3.4% | |
Fundraising Efficiency | $0.02 | |
Working Capital Ratio (years) | 1.88 | |
Program Expenses Growth | 29.0% | |
Liabilities to Assets | 14.9% |
REVENUE | |
Contributions | |
Contributions, Gifts & Grants | $2,271,112 |
Federated Campaigns | $0 |
Membership Dues | $0 |
Fundraising Events | $2,972,352 |
Related Organizations | $0 |
Government Grants | $0 |
Total Contributions | $5,243,464 |
Program Service Revenue | $0 |
Total Primary Revenue | $5,243,464 |
Other Revenue | $30,929 |
TOTAL REVENUE | $5,274,393 |
EXPENSES | |
Program Expenses | $2,668,012 |
Administrative Expenses | $194,505 |
Fundraising Expenses | $85,551 |
TOTAL FUNCTIONAL EXPENSES | $2,948,068 |
Payments to Affiliates | $0 |
Excess (or Deficit) for the year | $2,326,325 |
Net Assets | $7,573,733 |
Charts
Compensation | % of Expenses | Paid to | Title | Compensation from Affiliates |
---|---|---|---|---|
Not compensated | -- | Paula Evans | Chairperson | $145,833 |
Mission
The Foundation for Angelman Syndrome Therapeutics (FAST) is committed to accelerating treatments and a cure for Angelman syndrome (AS). The symptoms of AS have been under-addressed in the research community for far too long. Research aimed at identifying treatments for the motor dysfunction, seizures and behavioral characteristics of Angelman syndrome is one of FAST's top priorities. Our goal is to bring practical treatment into current medical practice as quickly as possible. It is our hope that grants we fund will lead to additional research support from government agencies, other funding sources and organizations around the globe.
Highly Rated
Charity Name & State | Overall Score | Overall Rating |
---|---|---|
Foundation for Angelman Syndrome Therapeutics (IL) | 92.22 | |
EB Research Partnership (NY) | 96.49 | |
MPN Research Foundation (IL) | 89.44 | |
Lupus Research Alliance (NY) | 91.39 | |
Rheumatology Research Foundation (GA) | 91.68 |